Abstract. Background: Vitamin D exhibits multiple anti-proliferative and pro-differentiating actions. Prostaglandin (PG) E2 is a tumor-promoting tissue hormone anabolized by cyclooxygenase-2 (COX-2). Recently, a link between the PG and vitamin D metabolism was reported. Materials and Methods: The influence of calcitriol and celecoxib on the proliferation of ovarian cancer cell lines was measured and the impact of calcitriol on the protein and mRNA expression of COX-2 was quantified by western blot and qRT-PCR, respectively. Results: After COX-2 induction with interleukin (IL)-1β, 10 μM celecoxib did not significantly inhibit the proliferation of OVCAR-3 cells, whereas calcitriol showed such an effect; however, the combination of the two substances had an additive influence. After induction by IL-1β, calcitriol inhibited the COX-2 protein, as well as its mRNA expression significantly in OVCAR-3 and SKOV-3 cells. Conclusion: These data suggest a correlation between PG and vitamin D metabolism in their anti-tumorigenic activity in ovarian carcinomas.

The estimated annual incidence of ovarian cancer in the USA for 2014 is 21,980 and approximately 14,270 deaths are expected (1). In Germany 7,790 new ovarian cancer cases were diagnosed and the estimated number for 2014 of new ovarian cancer cases in Germany is 7,500. In 2010, 5,599 women died of ovarian cancer (2). Thus, ovarian cancer is the leading cause of death from gynecological malignancies.

Correspondence to: Frank Köster, Dept. of Gynecology and Obstetrics, University of Lübeck, Ratzeburger Allee 160, D-23538 Lübeck, Germany. Tel: +49 451 5002163, Fax: +49 451 5004905, e-mail: frank.koester@uksh.de

Key Words: Vitamin D, celecoxib, cyclooxygenase-2, ovarian cancer.
DNA and regulates the transcriptional processing of genes that are relevant for vitamin D metabolism (8).

Obviously, a combination of calcitriol and non-steroidal anti-inflammatory drugs (NSAIDs) has a potential synergistic inhibiting effect on the tumorigenesis of breast cancer. Several studies have revealed that a combination of calcitriol and NSAIDs might be a useful chemopreventive and/or therapeutic strategy in prostate cancer (9-11).

Recently, our studies have suggested a link between the PG and vitamin D metabolisms in breast tumor cells (12) and breast cancer tissue (13); moreover, also in ovarian cancer tissue (14, 15).

Consequently, we hypothesize that a combination of COX-2 inhibition and calcitriol could increase an anti-proliferative effect on ovarian cancer cells and could offer new prevention or treatment approaches in the future. The aim of the present study was to analyze the influence of calcitriol and the selective COX-2 inhibitor celecoxib on the proliferation of ovarian cancer cell lines. We also examined the influence of calcitriol on COX-2 expression in ovarian cancer cell lines.

Materials and Methods

Cell culture and treatment. The ovarian cancer cell lines SKOV-3 and OVCAR-3 were purchased from LGC-Standards (Wesel, Germany). The cells were cultured in RPMI-1640 (Life Technologies, Karlsruhe, Germany) at 37°C in a humidified atmosphere containing 5% CO2. For treatment, the cells were plated in full media overnight by adding 100 μl stop-solution (10% (w/v) SDS, 50% FCS and 1% penicillin/streptomycin (both from PAA-Laboratories, Cölbe, Germany) at 37°C in a humidified atmosphere.

For the growth assays, cells were plated in full media overnight in 96-well or 6-well dishes to perform growth-assays or protein and mRNA analyses, respectively. The next day media were changed to 3% FCS containing the test-substances. For every concentration used, the substances were dissolved and diluted in pure DMSO at 1,000 x stocks for 1α,25-dihydroxyvitamin D3 (calcitriol) and 10,000 x stocks for celecoxib (both from Sigma, Taufkirchen, Germany). Therefore, 0.1% DMSO was used as a general solvent control.

Proliferation assays. To measure the influence of calcitriol on the proliferative activity in ovarian cancer cell lines 20,000 and 3,000 cells per well for BrdU and MTT-assays, respectively, were plated on 96-well plates in media containing 10% FCS. After 24 h, the media were exchanged with treatment media containing 3% FCS. Cells treated with calcitriol and/or celecoxib concentrations ranging from 0.1 to 10 μM were compared to solvent controlled cells with 0.1% DMSO added. After 24 h of treatment, the Cell Proliferation ELISA, BrdU (Roche, Mannheim, Germany) was performed according to the manufacturer’s recommendations. For MTT-assays, the media were exchanged after 72 h of treatment to 100 μl colorless media containing 10% MTT solution (5 mg/ml thiazolyl blue in PBS; Sigma) and cultivated for 4 h. Then, the reaction was stopped and dissolution of formazan crystals was performed in the dark by adding 100 μl stop-solution (10% (w/v) SDS, 50% N.N-dimethylformamide, pH 4.7). A microplate-reader was used to measure the absorption of the wells at 560 nm (Dynatech Laboratories-MRX, DPC Biermann, Bad Nauheim, Germany).

Immunochemical detection. The content of COX-2 protein in cells after treatment was compared to solvent controlled cells on western blots using a monoclonal COX-2 antibody (clone 33; BD-Transduction Laboratories, Heidelberg, Germany) and a β-actin antibody (clone AC-15; Sigma). Two hundred thousand cells were cultured in full media overnight in 96-well dishes to perform growth-assays or protein and mRNA analyses, respectively. The next day media were changed to 3% FCS containing the test-substances. For every concentration used, the substances were dissolved and diluted in pure DMSO at 1,000 x stocks for 1α,25-dihydroxyvitamin D3 (calcitriol) and 10,000 x stocks for celecoxib (both from Sigma, Taufkirchen, Germany). Therefore, 0.1% DMSO was used as a general solvent control.

Immunohistochemistry. Ovarian cancer tissue (14, 15).

Figure 1. Calcitriol inhibits the proliferation of ovarian cancer cell lines. The BrdU-ELISA in (A) OVCAR-3 and (B) in SKOV-3 cell line decreases proliferative activity after 24 h of treatment. Statistical significance is shown at p-values of * <0.05; ** <0.01 and *** <0.001.
Primer-Assay (Qiagen) was used and for normalization a sequence of the hypoxanthine-guanine phosphoribosyltranferase 1 (HPRT1) was amplified with the primers forward: 5'-TCA GGC AGT ATA ATC CAA AGA TGG T-3' and reverse: 5'-AGT CTG GCT TAT ATC CAA CAC TTC G-3' (synthesized at Metabion, Martinsried, Germany). The PCR protocol consisted of 42 cycles for 15 s at 95˚C and 30 s at 60˚C. Each sample was tested in triplicates. The reaction efficiency of each primer pair had been determined using dilution series with a representative pool of cDNAs as proposed by Pfaffl (16). Data were further processed with the excel-based program REST-MCS©-version 2 (www.gene-quantification.info).

Results

Influence of calcitriol on proliferation. Calcitriol significantly inhibits the proliferation of both tested ovarian cancer cell lines at concentrations of 10 nM to 50 μM measured in BrdU-ELISA (Figure 1). At 10 μM calcitriol OVCAR-3 and SKOV-3 were inhibited to 28% and 45%, respectively, compared to the solvent control.

Growth influence of combined treatment with calcitriol and celecoxib. The combination of calcitriol and celecoxib in OVCAR-3 cells was measured by the MTT-assay after 72-h treatment. Results are shown in Figure 2. For the activation of COX-2 expression and to imitate an inflammatory environment, the cells were treated in parallel with 1 ng/ml IL-1β. Celecoxib at 0.1, 1 and 10 μM could not significantly influence the growth of OVCAR-3 cells. Ten μM calcitriol was inhibiting the proliferation of OVCAR-3 cells to 70% compared to the solvent control IL-1β-treated cells. Combining celecoxib with 10 μM calcitriol, a significant additive effect could be measured at 10 μM celecoxib when compared to calcitriol treatment alone.

COX-2 expression under the influence of calcitriol. The expression of the COX-2 protein in the ovarian cancer cells after treatment with IL-1β (Figure 3; part A; lane 3) was activated as shown in the western blot to a strong band at 72 kDA in the OVCAR-3, as well as in SKOV-3 cell line, while DMSO (lane 2) had no such effect. Ten μM calcitriol added to IL-1β inhibited the COX-2 protein expression compared to IL-1β alone to an obviously diminished band (lane 5) in both cell lines. Calcitriol alone (lane 4) had no effect on COX-2 expression. The expression of the COX-2 gene is strongly activated after treatment with IL-1β as shown in Figure 3, part B for OVCAR-3 and in part C for SKOV-3 cells compared to the solvent containing control cultures. The addition of 10 μM calcitriol to IL-1β inhibited the activation of COX-2 mRNA expression from 10 times to 4 times and from 4 times to 2 times in OVCAR-3 and SKOV-3 cells, respectively. Calcitriol alone had no effect on the COX-2 expression.

Discussion

In the present study, we report for the first time, an additive inhibition of ovarian cancer cell proliferation by the combination of calcitriol and the selective COX-2 inhibitor celecoxib.
As we treated ovarian cancer cells with calcitriol, we received a strong inhibition of proliferation measured in the very sensitive BrdU incorporation assay. This proves the effect, which has been published by other groups before in various cancer cell lines derived from e.g. breast cancer (17-19), as well as in ovarian cancer cell lines (20). To reach the next step, we focused on the effects of a combination of celecoxib and calcitriol in ovarian cancer cells and if this combination interferes with the PG pathway. Whereas calcitriol again exhibited a significant reduction of cell growth, this response was much smaller than that in the BrdU-ELISA used in the previous experiment. Celecoxib was not significantly decreasing the ovarian cancer cell growth, although there was an inhibiting tendency of 10%. Herein, we used the less sensitive MTT-assay after 72 h of treatment, which might have been unfavorable. Kim et al. (21) found a 20% growth inhibition and the induction of apoptosis by 10 μM celecoxib. Therefore, a growth inhibiting effect can be assumed. The most meaningful result from this combination experiment was the significant inhibition of the combined application with celecoxib and calcitriol over calcitriol alone. Furthermore, we were asking if there were an interaction between the pathways of vitamin D and PG and we measured the COX-2 expression under the influence of calcitriol. At a first attempt, we could not detect any visual band in western blots using a COX-2 antibody neither in SKOV-3 nor in OVCAR-3 cells. The COX-2 expression had to be induced by simulating an inflammatory environment, which could be successfully created by the application of IL-1β. The combined application of calcitriol with IL-1β strongly interfered with the induction of the COX-2 expression. This could be shown on protein level, as well as at the level of mRNA expression (COX-2). Therefore, we presume a genomic regulation of the COX-2 gene by calcitriol. Recent publications reported of this regulative interaction found in MCF-7 breast cancer cells (22-23). Krishnan et al. performed a microarray based expression analysis of calcitriol application in various cancer cells and they found a reduction of the COX-2 mRNA in prostate cancer cells (24).

In several studies, COX-2 over-expression is associated with an increased proliferation and neoangiogenesis and, therefore, with a poor outcome of ovarian cancer patients (4-5, 25) and the antiproliferative effects of COX-2 inhibitors on cancer cells in vitro and in vivo are well known (21, 26-27). These facts lead to the idea of a COX-2 inhibition to gain a survival benefit for ovarian cancer patients. The selective COX-2 inhibitor celecoxib is able to induce apoptosis in different types of cancer (21, 28). Promising clinical data were presented by Legge et al. who included heavily pre-treated patients in a phase II study. The authors observed a good tolerability and activity of celecoxib added to carboplatin chemotherapy (29). However, a recently published phase II study by Reyners et al. did not show significant effects of 400 mg celecoxib on disease-free and overall survival when added to first-line chemotherapy in ovarian cancer patients (FIGO IC-FIGO IV) after surgery (30).

Several epidemiological studies have been published regarding the association between vitamin D and ovarian cancer risk; however all studies showed either no, or not a clear or only marginal associations of serum vitamin D levels with the risk of ovarian cancer (14-15, 31-32). Additionally, a meta-analysis by Yin et al. could not find any statistical significant inverse association between 25(OH)D serum level and ovarian cancer risk (33). In an actually published meta-analysis about VDR polymorphisms (vitamin D receptor) and ovarian cancer risk, only the Fokl polymorphisms (in the vitamin D receptor gene (VDR)) were associated with an increased ovarian cancer risk (34). However, experimental data support a role of the vitamin D pathway in ovarian carcinogenesis. A number of studies have observed that 1,25-dihydroxyvitamin D inhibits ovarian cancer cell growth (35-
and increases apoptosis (38). The Vitamin D analog EB1089 inhibits the proliferation of multiple ovarian cancer cell lines (including OVCAR-3) and reduces the growth of OVCAR-3 tumor xenografts in nude mice (39). In SCOV-3 cells, the first non-hypercalcaemic vitamin-D derivative MT19c had a higher cytotoxicity than EB1089 (40). Furthermore, Lange et al. utilized the calcidiol derivative B3CD in SKOV-3 and OVCAR-3 cells and reported a concentration-dependent cytotoxic and growth inhibitory effect in both cell lines (20). Moreover, high 1,25-dihydroxyvitamin D levels are able to increase VDR expression in ovarian cancer cell lines (38). As ovarian tissue expresses the VDR (15, 35, 37), existing data suggest that ovarian cancer has a functional vitamin D pathway that could potentially be a target for treatment or prevention (32). However, in our previous work we observed a significant lower VDR expression in ovarian cancer compared to normal tissue (15).

Based on several studies, summarized in a recent published review by Ma and co-workers, that have described the anti-proliferative and pro-apoptotic effect of calcitriol, calcitriol depicts a promising approach for the treatment of cancer (41). Calcitriol acts in multiple ways to influence cancer cell proliferation. It controls genes in PG metabolism, supports anti-inflammatory effects by an up-regulation of the mitogen-activated protein kinase phosphatase-5 expression (42), it influences the activation of nuclear factor-kappaB (NF-κB) (43). NF-κB is a transcription factor that regulates several genes involved in inflammatory and immune processes and likely plays a key role in the development from inflammation to carcinogenesis (44).

Calcitriol has been utilized in a number of pre-clinical and clinical studies as an antitumor agent in different carcinomas but not in ovarian cancer (45). Pre-clinical data suggest that calcitriol has to be given in very high amounts to induce antitumor effects and clinical data do indicate that very high doses of calcitriol (>100 μg weekly, intravenously and 0.15 μg/kg weekly orally) can be given safely (45). However, the maximum tolerated dose (MTD) of calcitriol is unclear. Because of the potential hypercalcaemic impact and the lack of a suitable available oral preparation, application is restricted and vitamin D analogues should be preferred (46-47). Some clinical trials regarding the use of calcitriol in combination with chemotherapy for cancer treatment exist, but the results are not satisfying (45). In the ASCENT I trial (AIPC Study of Calcitriol Enhancing Taxotere), pre-treated and advanced prostate cancer patients were treated with docetaxel + calcitriol but the study arm treatment was associated with shorter survival than the control arm (48).

Experiments with prostate cancer cells have shown that calcitriol inhibits cancer cell proliferation by influencing the PG metabolism: suppression of COX-2 expression, up-regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and reduction of PG receptors (9-11, 49). While inhibition of COX-2 in ovarian cancer is already under clinical evaluation, data to an inhibition with calcitriol, or even with the combination of calcitriol and COX-2 inhibition, are lacking. Our group published the only data showing a link between the PG and vitamin D metabolism in ovarian cancer cells and tissue. We demonstrated an inverse correlation between the vitamin D receptor (VDR) and the COX-2 expression and a lower PGE2 EP2 and EP4 receptor expression in ovarian cancer tissue (50). Moreover, we published data of ovarian cancer patients who had a higher PGE2 level compared to healthy women (14).

Our data suggest a correlation between vitamin D activities and the PG metabolism in ovarian carcinomas. Further research is required if the synergistic effect of this approach is a useful therapeutic strategy in treatment of ovarian cancer.

Acknowledgements

This work was supported by the Werner und Klara Kreitzz-Foundation, Kiel, Germany.

References


